Acurx Pharmaceuticals Llc Stock Today
| ACXP Stock | USD 1.25 0.10 8.70% |
Performance0 of 100
| Odds Of DistressOver 82
|
Acurx Pharmaceuticals is selling at 1.25 as of the 29th of November 2024; that is 8.70 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.0. Acurx Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Acurx Pharmaceuticals LLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of January 2023 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of June 2021 | Category Healthcare | Classification Health Care |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York. Acurx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 16.89 M outstanding shares of which 443.72 K shares are presently shorted by private and institutional investors with about 12.59 trading days to cover. More on Acurx Pharmaceuticals LLC
Moving against Acurx Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Acurx Stock Highlights
| President CoFounder | CPA Esq | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsAcurx Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Acurx Pharmaceuticals' financial leverage. It provides some insight into what part of Acurx Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Acurx Pharmaceuticals LLC (ACXP) is traded on NASDAQ Exchange in USA. It is located in 259 Liberty Avenue, Staten Island, NY, United States, 10305 and employs 4 people. Acurx Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.34 M. Acurx Pharmaceuticals LLC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 16.89 M outstanding shares of which 443.72 K shares are presently shorted by private and institutional investors with about 12.59 trading days to cover.
Acurx Pharmaceuticals LLC currently holds about 9.09 M in cash with (9.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.8.
Check Acurx Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationAcurx Pharmaceuticals holds a total of 16.89 Million outstanding shares. Acurx Pharmaceuticals LLC shows 14.8 percent of its outstanding shares held by insiders and 11.96 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Acurx Ownership Details
Acurx Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Patriot Financial Group Insurance Agency, Llc | 2024-09-30 | 10.4 K | |
| Tocqueville Asset Management L.p. | 2024-09-30 | 10 K | |
| Semmax Financial Advisors Inc. | 2024-06-30 | 5.9 K | |
| Group One Trading, Lp | 2024-06-30 | 5.2 K | |
| Tower Research Capital Llc | 2024-06-30 | 4.1 K | |
| Cornerstone Planning Group Llc | 2024-09-30 | 3.3 K | |
| Simplex Trading, Llc | 2024-06-30 | 2.9 K | |
| Northwestern Mutual Wealth Management Co | 2024-06-30 | 1.6 K | |
| Ubs Group Ag | 2024-06-30 | 881 | |
| Vanguard Group Inc | 2024-09-30 | 529.3 K | |
| Prospect Financial Services Llc | 2024-09-30 | 295.1 K |
Acurx Pharmaceuticals Historical Income Statement
Acurx Stock Against Markets
Already Invested in Acurx Pharmaceuticals LLC?
The danger of trading Acurx Pharmaceuticals LLC is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Acurx Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Acurx Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Acurx Pharmaceuticals LLC is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Acurx Stock Analysis
When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.